Boron containing small molecules
Compounds, pharmaceutical formulations, and methods of treating anti-inflammatory conditions and/or helminth-associated diseases are disclosed.
1. A method of decreasing the release of a cytokine or a chemokine, the method comprising: contacting a cell with the compound having a structure according to a formula which is selected from the group consisting of:
wherein
R d is selected from the group consisting of H, halogen, and unsubstituted alkyl;
R c is selected from the group consisting of cyano, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted alkoxy;
X is N or CH,
R b is selected from the group consisting of OR 4 and NR 4 R 5
wherein R 4 and R 5 are independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl,
with the proviso that R 4 and R 5 , together with the atoms to which they are attached, are optionally combined to form a 4- to 8-membered substituted or unsubstituted heterocycloalkyl ring
or a pharmaceutically acceptable salt thereof,
wherein the release of the cytokine or chemokine by the cell is decreased.
2. A method of treating psoriasis, atopic dermatitis, rheumatoid arthritis, an inflammatory bowel disease, asthma and chronic obstructive pulmonary disease, in an animal, the method comprising administering to the animal a therapeutically effective amount of the compound having a structure according to a formula which is selected from the group consisting of:
wherein
R d is selected from the group consisting of H, halogen, and unsubstituted alkyl;
R c is selected from the group consisting of cyano, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted alkoxy;
X is N or CH,
R b is selected from the group consisting of OR 4 and NR 4 R 5
wherein R 4 and R 5 are independently selected from the grow consisting of H, substituted or unsubstituted alkyl substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl,
with the proviso that R 4 and R 5 , together with the atoms to which they are attached, are optionally combined to form a 4- to 8-membered substituted or unsubstituted heterocycloalkyl ring
or a pharmaceutically acceptable salt thereof,
thereby treating the psoriasis, atopic dermatitis, rheumatoid arthritis, an inflammatory bowel disease, asthma and chronic obstructive pulmonary disease.
3. A method of inhibiting a phosphodiesterase (PDE), the method comprising: contacting the phosphodiesterase with a compound having a structure according to a formula which is selected from the group consisting of:
wherein
R d is selected from the group consisting of H, halogen, and unsubstituted alkyl;
R c is selected from the group consisting of cyano, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted alkoxy;
X is N or CH,
R b is selected from the group consisting of OR 4 and NR 4 R 5
wherein R 4 and R 5 are independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl,
with the proviso that R 4 and R 5 , together with the atoms to which they are attached, are optionally combined to form a 4- to 8-membered substituted or unsubstituted heterocycloalkyl ring
or a pharmaceutically acceptable salt thereof,
thereby inhibiting the phosphodiesterase.
4. The method of claim 3 , wherein said phosphodiesterase is phosphodiesterase4 (PDE4).